News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2023 Shelley Wood November 30, 2023
News Daily News Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs Michael O'Riordan November 27, 2023
Presentation AHA 2023 The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation Presenter: Jeff Healey November 16, 2023
News Conference News AHA 2023 ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF Todd Neale November 12, 2023
News Conference News AHA 2023 Off-label DOAC Dosing Common in Hospitalized AF Patients, Too Todd Neale November 07, 2023
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Daily News First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists L.A. McKeown August 31, 2023
News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
News Conference News ESC 2023 FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF Shelley Wood August 28, 2023
News Daily News Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis Todd Neale June 05, 2023
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2023 Shelley Wood May 31, 2023
News Conference News ESOC 2023 ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy Todd Neale May 25, 2023
News Conference News EuroPCR 2023 ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure Todd Neale May 18, 2023
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023